GGrantIndex
← Search

The Robert H. Lurie Comprehensive Cancer Center

$49,383P30FY2008CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

The Purdue Cancer Center was established in 1978 as an NCI-designated basic Cancer Center. The Center capitalizes on Purdue's nationally recognized strengths in the chemical and biological sciences to focus institutional expertise on the cancer problem. The interface between chemistry and biology is exploited in the interprogrammatic collaborations that the Center fosters, and this represents a fundamental and unique strength of this Cancer Center. The Center's three scientific programs integrate chemical design and synthesis, protein structural analysis and molecular mechanisms of cell growth to form a network of collaborative science that crosses multiple disciplines. This synergism derives from the Center's focus on interdisciplinary research as the key to progress in controlling cancer. Emphasis in the Experimental Therapeutics and Diagnostic (ETD) program is on the creation of new chemical entities to improve the diagnosis and treatment of cancer. Scientists in the Structural Biology (SB) program provide the structural framework for the rational design of future therapeutics and delivery vehicles, while investigators in the Cell Growth and Differentiation (CGD) program discover and characterize molecules and cellular processes for use as novel cancer targets. In addition to its scientific programs, the Center fosters fundamental cancer research through four Center-sponsored focus groups, a Small Grants Program, and annual retreats and seminar programs. The three scientific programs are served by seven shared resources that are supported in part by the Cancer Center Support Grant: Analytical Cytology; DNA Sequencing; Drug Discovery: Macromolecular Crystallography; Mass Spectrometry; Nuclear Magnetic Resonance; and Transgenic Mouse. The Cancer Center Support Grant also provides funds for the strategic recruitment of new cancer-focused investigators to the Center, for planning and evaluation, and for administration and organization of the Center.

View original record on NIH RePORTER →